Vector BioMed's Major Upcoming Presentations
Vector BioMed is preparing for significant visibility in the biotechnology scene, with plans to showcase its latest advancements at two prominent industry events this May. These events are designed for professionals in the field of cell and gene therapy. The focus will be on the revolutionary LENTIVERSE platform aimed at enhancing access to cutting-edge gene therapies.
Innovative LENTIVERSE Platform Unveiling
At these conferences, the spotlight will be on the LENTIVERSE platform, which represents a transformative leap in lentiviral vector production. This initiative is not merely a platform; it represents an entire modular ecosystem intended to dismantle existing barriers that hinder accessibility in cell and gene therapies.
Dr. Boro Dropulic, the CEO of Vector BioMed, will engage with attendees at the International Society for Cell & Gene Therapy (ISCT) event. He will detail critical strategies that are essential for revolutionizing the landscape of cell and gene therapy. One of the key points he will address is how the company aims to exponentially decrease the time it takes to bring these therapies from the laboratory to the clinic and make them accessible globally.
Presentation and Exhibit Details
The upcoming ISCT session, titled "The Next Frontier in Lentiviral Manufacturing", is poised to be a highlight. On May 8, Dr. Dropulic is set to cover how new lentiviral design and decentralized manufacturing approaches are effectively dismantling the long-standing hurdles of high costs and complexity associated with gene therapy. This session will provide essential insights into evolving commercial-friendly solutions that enable faster patient access and scalable international outreach.
Vector BioMed will also be actively exhibiting at the ASGCT event from May 13-17, where they will be stationed at booth 1348. Visitors are encouraged to explore how the LENTIVERSE platform is poised to reshape the landscape of viral vector innovation and significantly expand access to groundbreaking therapies.
A Commitment to Accessible Gene Therapies
Vector BioMed operates as a public benefit corporation with a mission to make lentiviral vector manufacturing more accessible and affordable. The company emerged from the nonprofit sector and has developed a robust support system for biotech startups, research institutions, and global health initiatives. Its offerings include customizable vector solutions aimed at simplifying the development process and bridging the gap to innovative cures.
Dr. Dropulic's comments underline the company’s commitment: "We've reached an inflection point in gene therapy where affordable and innovative vector production is a must to pull science forward (to market), together with innovators." The introduction of the LENTIVERSE platform is a clear alignment with these goals, aiming to create a holistic support framework for cell and gene therapy developers.
Contact Information
For press inquiries, Bryce Goodman serves as the Director of Marketing and Communications at Vector BioMed. He is available at 440-315-1796 for interviews and information regarding the company's innovations and upcoming presentations.
Frequently Asked Questions
What is Vector BioMed?
Vector BioMed is a public benefit corporation focused on redefining lentiviral vector manufacturing for affordable gene therapies.
Where will Vector BioMed be presenting?
Vector BioMed will present at the ISCT and ASGCT conferences showcasing their LENTIVERSE platform.
Who is the CEO of Vector BioMed?
Dr. Boro Dropulic is the CEO of Vector BioMed, leading in innovative gene therapy solutions.
What is the LENTIVERSE platform?
The LENTIVERSE platform is a modular ecosystem designed to enhance the efficiency and accessibility of lentiviral vector production.
How can I contact Vector BioMed for media inquiries?
You can contact Bryce Goodman, the Director of Marketing and Communications, for press inquiries and information related to their innovations.
